Research ExplorerPublicationsPopulation pharmacokinetics of meropenem during continuous i...

Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients

Standard

Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. / Kees, Martin G; Minichmayr, Iris K; Moritz, Stefan; Beck, Stefanie; Wicha, Sebastian G; Kees, Frieder; Kloft, Charlotte; Steinke, Thomas.

In: J CLIN PHARMACOL, Vol. 56, No. 3, 03.2016, p. 307-15.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kees, MG, Minichmayr, IK, Moritz, S, Beck, S, Wicha, SG, Kees, F, Kloft, C & Steinke, T 2016, 'Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients', J CLIN PHARMACOL, vol. 56, no. 3, pp. 307-15. https://doi.org/10.1002/jcph.600

APA

Kees, M. G., Minichmayr, I. K., Moritz, S., Beck, S., Wicha, S. G., Kees, F., Kloft, C., & Steinke, T. (2016). Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J CLIN PHARMACOL, 56(3), 307-15. https://doi.org/10.1002/jcph.600

Vancouver

Kees MG, Minichmayr IK, Moritz S, Beck S, Wicha SG, Kees F et al. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J CLIN PHARMACOL. 2016 Mar;56(3):307-15. https://doi.org/10.1002/jcph.600

Bibtex

@article{c7c0aa0c1576463cab6d1e132047850a,
title = "Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients",
abstract = "Continuous infusion of meropenem is a candidate strategy for optimization of its pharmacokinetic/pharmacodynamic profile. However, plasma concentrations are difficult to predict in critically ill patients. Steady-state concentrations of meropenem were determined prospectively during continuous infusion in 32 surgical ICU patients (aged 21-85 years, body weight 55-125 kg, APACHE II 5-29, measured creatinine clearance 22.7-297 mL/min). Urine was collected for the quantification of renal clearance of meropenem and creatinine. Cystatin C was measured as an additional marker of renal function. Population pharmacokinetic models were developed using NONMEM({\textregistered}) , which described total meropenem clearance and its relationship with several estimates of renal function (measured creatinine clearance CLCR , Cockcroft-Gault formula CLCG , Hoek formula, 1/plasma creatinine, 1/plasma cystatin C) and other patient characteristics. Any estimate of renal function improved the model performance. The strongest association of clearance was found with CLCR (typical clearance = 11.3 L/h × [1 + 0.00932 × (CLCR  - 80 mL/min)]), followed by 1/plasma cystatin C; CLCG was the least predictive covariate. Neither age, weight, nor sex was found to be significant. These models can be used to predict dosing requirements or meropenem concentrations during continuous infusion. The covariate CLCR offers the best predictive performance; if not available, cystatin C may provide a promising alternative to plasma creatinine.",
author = "Kees, {Martin G} and Minichmayr, {Iris K} and Stefan Moritz and Stefanie Beck and Wicha, {Sebastian G} and Frieder Kees and Charlotte Kloft and Thomas Steinke",
note = "{\textcopyright} 2015, The American College of Clinical Pharmacology.",
year = "2016",
month = mar,
doi = "10.1002/jcph.600",
language = "English",
volume = "56",
pages = "307--15",
journal = "J CLIN PHARMACOL",
issn = "0091-2700",
publisher = "SAGE Publications",
number = "3",

}

RIS

TY - JOUR

T1 - Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients

AU - Kees, Martin G

AU - Minichmayr, Iris K

AU - Moritz, Stefan

AU - Beck, Stefanie

AU - Wicha, Sebastian G

AU - Kees, Frieder

AU - Kloft, Charlotte

AU - Steinke, Thomas

N1 - © 2015, The American College of Clinical Pharmacology.

PY - 2016/3

Y1 - 2016/3

N2 - Continuous infusion of meropenem is a candidate strategy for optimization of its pharmacokinetic/pharmacodynamic profile. However, plasma concentrations are difficult to predict in critically ill patients. Steady-state concentrations of meropenem were determined prospectively during continuous infusion in 32 surgical ICU patients (aged 21-85 years, body weight 55-125 kg, APACHE II 5-29, measured creatinine clearance 22.7-297 mL/min). Urine was collected for the quantification of renal clearance of meropenem and creatinine. Cystatin C was measured as an additional marker of renal function. Population pharmacokinetic models were developed using NONMEM(®) , which described total meropenem clearance and its relationship with several estimates of renal function (measured creatinine clearance CLCR , Cockcroft-Gault formula CLCG , Hoek formula, 1/plasma creatinine, 1/plasma cystatin C) and other patient characteristics. Any estimate of renal function improved the model performance. The strongest association of clearance was found with CLCR (typical clearance = 11.3 L/h × [1 + 0.00932 × (CLCR  - 80 mL/min)]), followed by 1/plasma cystatin C; CLCG was the least predictive covariate. Neither age, weight, nor sex was found to be significant. These models can be used to predict dosing requirements or meropenem concentrations during continuous infusion. The covariate CLCR offers the best predictive performance; if not available, cystatin C may provide a promising alternative to plasma creatinine.

AB - Continuous infusion of meropenem is a candidate strategy for optimization of its pharmacokinetic/pharmacodynamic profile. However, plasma concentrations are difficult to predict in critically ill patients. Steady-state concentrations of meropenem were determined prospectively during continuous infusion in 32 surgical ICU patients (aged 21-85 years, body weight 55-125 kg, APACHE II 5-29, measured creatinine clearance 22.7-297 mL/min). Urine was collected for the quantification of renal clearance of meropenem and creatinine. Cystatin C was measured as an additional marker of renal function. Population pharmacokinetic models were developed using NONMEM(®) , which described total meropenem clearance and its relationship with several estimates of renal function (measured creatinine clearance CLCR , Cockcroft-Gault formula CLCG , Hoek formula, 1/plasma creatinine, 1/plasma cystatin C) and other patient characteristics. Any estimate of renal function improved the model performance. The strongest association of clearance was found with CLCR (typical clearance = 11.3 L/h × [1 + 0.00932 × (CLCR  - 80 mL/min)]), followed by 1/plasma cystatin C; CLCG was the least predictive covariate. Neither age, weight, nor sex was found to be significant. These models can be used to predict dosing requirements or meropenem concentrations during continuous infusion. The covariate CLCR offers the best predictive performance; if not available, cystatin C may provide a promising alternative to plasma creatinine.

U2 - 10.1002/jcph.600

DO - 10.1002/jcph.600

M3 - SCORING: Journal article

C2 - 26222202

VL - 56

SP - 307

EP - 315

JO - J CLIN PHARMACOL

JF - J CLIN PHARMACOL

SN - 0091-2700

IS - 3

ER -